Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Dec;14(12):1660-6.
doi: 10.1002/ibd.20520.

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis

Affiliations
Randomized Controlled Trial

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis

James D Lewis et al. Inflamm Bowel Dis. 2008 Dec.

Abstract

Background: The Mayo score and a noninvasive 9-point partial Mayo score are used as outcome measures for clinical trials assessing therapy for ulcerative colitis (UC). There are limited data assessing what defines a clinically relevant change in these indices. We sought to assess what constitutes a clinically meaningful change in these indices using data from a recently completed placebo-controlled clinical trial.

Methods: In all, 105 patients were enrolled in a 12-week randomized, placebo-controlled trial assessing rosiglitazone for treatment of mild to moderate UC. We compared the change in the Mayo score, the partial Mayo score, and a 6-point score composed just of the stool frequency and bleeding components of the Mayo score to the patient's perception of disease activity at week 0 and week 12. Optimal cutpoints were calculated as the maximal product of sensitivity and specificity.

Results: Each index was strongly correlated with the patient's rating of disease activity at week 12 (Spearman correlations 0.61-0.71, P < 0.0001 for all correlations). The maximal product of sensitivity and specificity to identify patient reported improvement of disease activity was achieved using cutpoints for change of 2.5 for the Mayo score (sensitivity 88%, specificity 80%), 2.5 for the partial Mayo score (sensitivity 88%, specificity 87%), and 1.5 for the 6-point score (sensitivity 88%, specificity 80%).

Conclusions: The partial Mayo score and the 6-point score composed solely of the stool frequency and bleeding components performed as well as the full Mayo score to identify patient perceived clinical response.

Trial registration: ClinicalTrials.gov NCT00065065.

PubMed Disclaimer

Conflict of interest statement

The authors report no potential conflicts of interest related to this study.

Figures

Figure 1
Figure 1
Comparison of ROC curves for the Mayo score, the partial Mayo score, and the 6 Point Score to identify patient-defined remission. The area under the curve was less for the 6 Point Score than for the Mayo and partial Mayo scores (p=0.03).
Figure 2
Figure 2
Comparison of ROC curves for the Mayo score, the partial Mayo score, and the 6 Point Score to identify patient-defined clinical improvement. There was no significant difference in the area under the three curves (p=0.48).

References

    1. D’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763–86. - PubMed
    1. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782–8. - PMC - PubMed
    1. Higgins PD, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? American Journal of Gastroenterology. 2005;100:355–61. - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2005;353:2462–76. - PubMed
    1. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. American Journal of Gastroenterology. 2001;96:3323–8. - PubMed

Publication types

Associated data